Andere Sprachen Bausch + Lomb Corporation

Aktien

A3DLMS

CA0717051076

BLCO

Markt geschlossen - Nyse Andere Börsenplätze 22:00:02 02.05.2024			% 5 Tage	% 1. Jan.
13.86 ^USD	+0.87%		-6.10%	-18.76%

02.05.	RBC Capital bewertet die Q1-Ergebnisse von Bausch + Lomb	MT
02.05.	BAUSCH + LOMB CORPORATION : Deutsche Bank Securities bekräftigt seine neutrale Bewertung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Bausch Health Announces First Quarter 2024 Results	12:59
RBC Capital Reviews Bausch + Lomb's Q1 Results	02.05.
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	01.05.
Bausch + Lomb Q1 Loss Widens, Revenue Increases	01.05.
Bausch + Lomb Q1 Net Loss Widens, But Revenue Higher; Raises 2024 Revenue Growth Guidance	01.05.
Bausch + Lomb: Q1 Earnings Snapshot	01.05.
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance	01.05.
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million	01.05.
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million	01.05.
Bausch + Lomb Announces First-Quarter 2024 Results	01.05.
Bausch + Lomb Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	01.05.
Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting	29.04.
Bausch + Lomb Says Study Shows Improvements in Dry Eyes With Nutritional Supplement	25.04.
Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes	25.04.
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	25.04.
Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	25.04.
Bausch + Lomb Corporation Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	25.04.
RBC Previews Bausch Health's Q1, Trims Target to US$11	23.04.
RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1	22.04.
Bausch + Lomb Q1 Results Likely to be Impacted by Foreign Exchange Headwinds, RBC Says	22.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Bausch + Lomb Corporation

Aktien

A3DLMS

CA0717051076

BLCO

Andere Sprachen

Filter